Table 2.

Application of siRNA and chemotherapeutics combination strategies in the therapy of pancreatic cancer

S.No.	Nanocarrier/ Other type of Carrier	Targeting ligand	In vivo model	Route of administration	Combination	Cell line	Result	Ref.
1.	Lipid NP	HIFIα	Mouse	Intravenous	siRNA and GEM	Panc-1	Prevention in burst release and boosted cytoxicity of GEM	[113]
2.	Lipid NP	HIFIα	Mouse	Intravenous	siRNA and GEM	Panc-1	Increased intracellular concentration and reduction in tumour weight	[114]
3.	Lipid NP	KRAS	Mouse	Intravenous	siRNA and GEM	Panc-1	Decreased tumour proliferation, enhanced apoptosis and no toxicity	[115]
4.	Lipid NP	Mcl-1	Mouse	Intravenous	siRNA and GEM	BxPC3 and Panc-1	Higher cellular uptake, prevention of siRNA from nuclease degradation and overcomes GEM resistance	[116]
5.	Lipid NP	RRM2	Mouse	Intraperitoneal and Peritumoral	siRNA and DOX	Panc-1	Reduction in tumour growth, decreased metastasis and DOX dose	[117]
6.	Polymer NP	PLK 1	Mouse	Intraperitoneal	siRNA and GEM	KPC8060 and S2–013	Greater accumulation in tumours and significant increase in anti-cancer activity	[118]
7.	Dendrimer	ITCH	Mouse	Subcutaneous	siRNA and GEM	Mia-PaCa-2, BxPC3 and Panc-1	Significant gene knockdown and increased chemo sensitivity	[43]
8.	Gold NP	KRAS	Mouse	Intratumoral	siRNA and DOX	Panc-1	Reduction in tumour growth by 90%	[119]
9.	Magnetic NP	PD-L1	Mouse	Intravenous	siRNA and GEM	PAN-02	Supressed tumour growth and improved survival rates	[120]
10.	Implant	KRAS	Mouse and Human Patients	Subcutaneous	siRNA and GEM	–	Sustained release of drug, prevention of siRNA from serum degradation and enhanced overall survival rates	[121]
11.	Biodegradable construct	CHK1	–	–	siRNA and GEM	Mia-PaCa-2, BxPC3,Panc-1 and CEPAC-1	Reduction in GEM dose and enhanced efficacy	[122]
12.	Polyester based vectors	Notch-1 and KRAS	–	–	siRNA and GEM	Mia-PaCa-2	Increased apoptosis and chemo sensitivity	[123]